Promising combo tackles rare spine tumor
NCT ID NCT02989636
First seen Jan 08, 2026 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This early-stage trial tests whether adding an immunotherapy drug (nivolumab) to precise radiation (stereotactic radiosurgery) is safe for people with chordoma that has returned or spread. The study enrolls 21 adults with confirmed chordoma and aims to find the best dose and check for serious side effects. It does not offer a cure but may help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.